Decreased expression of PPARG and increased expression of PTGS2 (Prostaglandin Endoperoxide Synthase 2) has also been shown to be associated with the prognosis of lung cancer, treatment with PPARG agonists lead to a decrease in the levels of PTGS2 thus inhibiting the growth of NSCLC (Hazra et al., 2008). This evidence concerns the gene PTGS2 and lung carcinoma.